Bioanalysis,
Год журнала:
2021,
Номер
13(21), С. 1597 - 1616
Опубликована: Окт. 28, 2021
Flow
cytometry
is
a
powerful
technology
used
in
research,
drug
development
and
clinical
sample
analysis
for
cell
identification
characterization,
allowing
the
simultaneous
interrogation
of
multiple
targets
on
various
subsets
from
limited
samples.
Recent
advancements
instrumentation
fluorochrome
availability
have
resulted
significant
increases
complexity
dimensionality
flow
panels.
Though
this
increase
panel
size
allows
detection
broader
range
markers
sub-populations,
even
restricted
biological
samples,
it
also
comes
with
many
challenges
design,
optimization,
downstream
data
interpretation.
In
current
paper
we
describe
practices
established
high-dimensional
panels
Aurora
spectral
cytometer
to
aid
analysis.
Proteomes,
Год журнала:
2024,
Номер
12(1), С. 8 - 8
Опубликована: Март 18, 2024
Ovarian
cancer
is
one
of
the
deadliest
cancers
in
women.
The
lack
specific
symptoms,
especially
at
initial
stages
disease
development,
together
with
malignancy
heterogeneity,
lower
life
expectancy
patients.
Aiming
to
improve
survival
rates,
diagnostic
and
prognostic
biomarkers
are
increasingly
employed
clinics,
providing
gynecologists
oncologists
new
tools
guide
their
treatment
decisions.
Despite
vast
number
investigations,
there
still
an
urgent
need
discover
more
ovarian
subtype-specific
markers
which
could
further
patient
classification.
To
this
end,
high-throughput
screening
technologies,
like
mass
spectrometry,
applied
deepen
tumoral
cellular
landscape
describe
malignant
phenotypes.
As
for
treatment,
targeted
therapies,
such
as
those
based
on
PARP
inhibitors,
have
shown
great
efficacy
destroying
cells.
Likewise,
drug-nanocarrier
systems
targeting
cells
exhibited
promising
results.
In
narrative
review,
we
summarize
latest
achievements
pursuit
recent
anti-tumoral
therapies.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(2), С. 1201 - 1201
Опубликована: Янв. 18, 2024
Cancer
stands
as
the
leading
global
cause
of
mortality,
with
rare
cancer
comprising
230
distinct
subtypes
characterized
by
infrequent
incidence.
Despite
inherent
challenges
in
addressing
diagnosis
and
treatment
cancers
due
to
their
low
occurrence
rates,
several
biomedical
breakthroughs
have
led
significant
advancement
both
areas.
This
review
provides
a
comprehensive
overview
state-of-the-art
diagnostic
techniques
that
encompass
new-generation
sequencing
multi-omics,
coupled
integration
artificial
intelligence
machine
learning,
revolutionized
diagnosis.
In
addition,
this
highlights
latest
innovations
therapeutic
options,
immunotherapy,
targeted
therapy,
transplantation,
drug
combination
undergone
clinical
trials
significantly
contribute
tumor
remission
overall
survival
patients.
review,
we
summarize
recent
insights
understanding
pathophysiology,
diagnosis,
modalities,
well
faced
development
data
interpretation
development.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research,
Год журнала:
2022,
Номер
1869(8), С. 119266 - 119266
Опубликована: Апрель 4, 2022
Despite
the
dynamic
development
of
cancer
research,
annually
millions
people
die
cancer.
The
human
immune
system
is
major
'guard'
against
tumor
development.
Unfortunately,
cells
have
ability
to
evade
and
continue
grow.
proper
understanding
intricate
response
in
tumorigenesis
remains
holy
grail
immunology
designing
effective
immunotherapy.
To
decode
responses
cancer,
recent
years,
proteomics
studies
received
considerable
attention.
Proteomics
focus
on
detection
quantification
proteins,
which
are
effectors
biological
functions,
as
such,
proven
reflect
cell
state
more
accurately,
comparison
genomic
or
transcriptomic
studies.
In
this
review,
we
discuss
applied
characterize
microenvironment
heterogeneity.
Further,
describe
emerging
single-cell
approaches
that
potential
be
immunity
Cytometry Part A,
Год журнала:
2022,
Номер
101(11), С. 942 - 959
Опубликована: Май 20, 2022
High-dimensional
single-cell
data
has
become
an
important
tool
in
unraveling
the
complexity
of
immune
system
and
its
involvement
homeostasis
a
large
array
pathologies.
As
technological
tools
are
developed,
researchers
adopting
them
to
answer
increasingly
complex
biological
questions.
Up
until
recently,
mass
cytometry
(MC)
been
main
technology
employed
cytometric
assays
requiring
more
than
29
markers.
Recently,
however,
with
introduction
full
spectrum
flow
(FSFC),
it
possible
break
fluorescence
barrier
go
beyond
fluorescent
parameters.
In
this
study,
collaboration
Stanford
Human
Immune
Monitoring
Center
(HIMC),
we
compared
five
patient
samples
using
established
panel
developed
by
HIMC
their
MC
platform.
Using
split
same
antibody
panel,
were
able
demonstrate
highly
comparable
results
between
two
technologies
multiple
analysis
approaches.
We
report
here
direct
comparison
platforms
(MC
FSFC)
32-marker
monitoring
that
can
identify
all
previously
described
anticipated
subpopulations
defined
panel.
Frontiers in Immunology,
Год журнала:
2021,
Номер
12
Опубликована: Июль 12, 2021
Single-cell
molecular
tools
have
been
developed
at
an
incredible
pace
over
the
last
five
years
as
sequencing
costs
continue
to
drop
and
numerous
assays
coupled
readouts.
This
rapid
period
of
technological
development
has
facilitated
delineation
individual
characteristics
including
genome,
transcriptome,
epigenome,
proteome
cells,
leading
unprecedented
resolution
networks
governing
complex
biological
systems.
The
immense
power
single-cell
screens
particularly
highlighted
through
work
in
systems
where
cellular
heterogeneity
is
a
key
feature,
such
stem
cell
biology,
immunology,
tumor
biology.
Single-cell-omics
technologies
already
contributed
identification
novel
disease
biomarkers,
subsets,
therapeutic
targets
diagnostics,
many
which
would
undetectable
by
bulk
approaches.
More
recently,
efforts
integrate
multi-omics
with
single
functional
output
and/or
physical
location
challenging
but
led
substantial
advances.
Perhaps
most
excitingly,
there
are
emerging
opportunities
reach
beyond
description
static
states
recent
advances
modulation
cells
CRISPR
technology,
particular
base
editors
greatly
raises
prospect
gene
therapies.
In
this
review,
we
provide
brief
overview
discuss
current
developments
integrating
performing
for
clinical
applications.
We
also
how
can
be
usefully
combined
data
unpick
mechanism
decision-making.
Finally,
reflect
upon
introduction
spatial
transcriptomics
proteomics,
its
complementary
role
RNA
(scRNA-seq)
potential
application
therapy.
